Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Gynecol Oncol. 2016 Jul 19;143(1):143–151. doi: 10.1016/j.ygyno.2016.07.088

Figure 3. Panobinostat enhances the growth inhibitory effects of olaparib in HR-proficient ovarian cancer cells.

Figure 3

A) SRB assay showing combination effects the panobinostat pre-treatment (1–20nM; 24h)/panobinostat (1–20nM) and olaparib (2–40µM) co-treatment combination regimen (72h) in HR-proficient ovarian cancer cell lines, OVCAR-3, OVCAR-4, SKOV-3 and BRCA1 WT cells. B) Combination Index (CI) for ED(Effective Dose)50, ED75 and ED90 was calculated by isobologram analysis. CI < 1 is synergistic. All CI’s were p<0.05 compared to a CI of 1, Student’s t test. N/A not applicable. C) Effects of the panobinostat pre-treatment (25nM; 24h)/panobinostat (25nM; 24h) and olaparib (10µM) co-treatment combination regimen (24h) in clonogenic assays 7–10 days after drug withdrawal. D) Clonogenicity was measured by cumulative staining intensity in triplicate wells. Values in A), B) and D) are mean+SD of 3 independent experiments. *p<0.01 compared to vehicle; ap<0.01 relative to olaparib alone; bp<0.01 relative to panobinostat alone, all Student’s t test.